SCHEMBL22718031

SCHEMBL22718031

COc1ccc(CN(C)S(=O)(=O)c2ccc(Nc3cccc(C(F)(F)F)n3)c(-c3cn(C)cn3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 1/20 0.44
▸ YAP1 P46937 1/20 0.44
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TYK2 P29597 2/20 0.37
▸ SYK P43405 2/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ DYRK3 O43781 1/20 0.37
▸ MAP4K4 O95819 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ RET P07949 1/20 0.37
▸ ROS1 P08922 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ FER P16591 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ CLK2 P49760 1/20 0.37
▸ PLK1 P53350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438837 1.00 TEAD1 (0.44) TEAD1YAP1MEN1KMT2ATYK2
SCHEMBL29438846 0.89 TEAD1 (0.45) TEAD1YAP1MEN1KMT2AKDM4E
SCHEMBL22718180 0.89 TEAD1 (0.45) TEAD1YAP1MEN1KMT2AKDM4E
SCHEMBL22718156 0.86 MEN1 (0.42) TEAD1YAP1MEN1KMT2ATAS2R14
SCHEMBL29438833 0.86 MEN1 (0.42) TEAD1YAP1MEN1KMT2ATAS2R14
SCHEMBL22718289 0.86 TEAD1 (0.47) TEAD1YAP1MEN1KMT2ASYK
SCHEMBL29438915 0.86 TEAD1 (0.49) TEAD1YAP1MEN1KMT2AKDM4E
SCHEMBL22718251 0.86 TEAD1 (0.49) TEAD1YAP1MEN1KMT2AKDM4E
SCHEMBL29438917 0.86 TEAD1 (0.49) TEAD1YAP1MEN1KMT2AKDM4E
SCHEMBL29438894 0.86 TEAD1 (0.47) TEAD1YAP1MEN1KMT2ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885MEN1 3307/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885MEN1 3307/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885MEN1 3307/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885MEN1 3307/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 TEAD1 7/4885YAP1 13/4885MEN1 3/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885MEN1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback